Clinical Trials Logo

Filter by:
NCT ID: NCT02928120 Recruiting - Clinical trials for Colorectal Neoplasms

Diagnostic Potential of Hypermethylated DNA in Colorectal Cancer

Start date: February 2015
Phase: N/A
Study type: Observational

Colorectal cancer (CRC) is one of the most common forms of cancer and the second leading cause of cancer-related deaths in the western world. CRC mortality is related to stage of disease with a five year survival for early-stage disease of 77.0% and 50.8% for late stage disease. Methods for early detection of primary as well as recurrent CRC are therefore important to increase patient survival. Tumour biomarkers from blood, stool, or urine could aid the early diagnostics of CRC, but despite extensive research such markers have only provided limited clinical value. Sporadic CRC develops as a result of the accumulation of genetic and epigenetic alterations. Epigenetic alterations include DNA hypermethylation, which through transcriptional silencing of tumour suppressor genes is associated with cancer development and cancer progression. The search for gene promoter regions hypermethylated in cancer has been ongoing for nearly two decades, and a number of genes have been shown to be preferentially hypermethylated in CRC. Therefore, hypermethylated DNA in plasma has been suggested as a marker for tumour-stage and survival in CRC patients. The only approved biomarker for the detection of CRC recurrence is the protein carcinoembryonic antigen (CEA). CEA is limited by its low sensitivity and therefore not recommended as a diagnostic biomarker. Hypermethylation of CRC specific genes as part of a molecular biomarker panel measured in blood could prove to be a recurrence marker in CRC patients, with elevated sensitivity and specificity. The aims of this project are to examine if hypermethylation of specific genes measured from cell-free DNA in plasma of CRC patients can be used to detect primary CRC, to detect CRC recurrence and to be a biomarker for CRC prognosis. Development of a reliable sensitive and specific biomarker for CRC will immensely improve the diagnostics and handling of CRC patients.

NCT ID: NCT02926053 Recruiting - Clinical trials for Metastatic Renal Cell Carcinoma

TIL Therapy for Metastatic Renal Cell Carcinoma

Start date: December 2016
Phase: Phase 1
Study type: Interventional

Adoptive T cell therapy (ACT) with tumor infiltrating lymphocytes (TIL) has achieved impressive clinical results with durable complete responses in patients with metastatic melanoma. The TILs are isolated from patients own tumor tissue followed by in vitro expansion and activation for around 4-6 weeks. Before TIL infusion the patients receive 1 week of preconditioning chemotherapy with cyclophosphamide and fludarabine. After TIL infusion Interleukin-2 is administered to support T cell activation and proliferation in vivo. Recent studies suggest, that TIL therapy works in other cancers than Metastatic Melanoma, including Renal Cell Carcinoma. In this study TIL therapy is administered to patients with metastatic Renal Cell Carcinoma.

NCT ID: NCT02914873 Recruiting - Prostate Cancer Clinical Trials

SPCG17: Prostate Cancer Active Surveillance Trigger Trial

PCASTT
Start date: October 2016
Phase: N/A
Study type: Interventional

A large proportion of men with prostate cancer are overdiagnosed and overtreated mainly due to PSA testing. Active surveillance (AS) aims to reduce these harms by recommending curative treatment only when and if signs of tumor progression occur. There are however a number of uncertainties in AS, the most important being when to initiate treatment. The investigators are therefore starting a large randomized multicenter trial testing the safety of a standardized active surveillance protocol with specified triggers for repeat biopsies and initiation of curative treatment. The standardized protocol is compared with current practice for active surveillance. The primary aim of the study is to reduce overtreatment and subsequent side effects, without increasing the risk of disease progression or prostate cancer mortality.

NCT ID: NCT02912949 Recruiting - NRG1 Fusion Clinical Trials

A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

Start date: January 2015
Phase: Phase 2
Study type: Interventional

This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion (eNRGy)

NCT ID: NCT02903719 Recruiting - Surgery Clinical Trials

The Effect of Phrenic Nerve Block on Postoperative Shoulder Pain in Patients for Liver Resection.

Start date: September 2016
Phase: Phase 4
Study type: Interventional

The aim of this study is to explore whether the use of ultrasound guided phrenic nerve block can reduce the postoperative pain in the shoulder after liver resection. The intervention is directed postoperative to the patients experiencing novel right sided shoulder pain.

NCT ID: NCT02898532 Recruiting - ADHD Clinical Trials

Children With ADHD and ADHD-like Symptoms and Target Shooting Sport in Danish Shooting Associations.

Start date: January 2016
Phase: N/A
Study type: Interventional

Practising target shooting sport requires focused attention and motoric steadiness. Parental reports suggest that children with attention-deficit/hyperactivity disorder (ADHD) benefit from participating in target shooting sport in Danish Shooting Associations. Aim: This study aims at examining if and to which extent target shooting sport in children with attention difficulties reduces parent- and teacher-reported severity of inattentiveness, hyperactivity, and impulsivity, and improves the children's well-being and quality of life.

NCT ID: NCT02893215 Recruiting - Atrial Fibrillation Clinical Trials

Silent Atrial Fibrillation - Screening of High-risk Groups for Atrial Fibrillation (The Silence Study)

Start date: November 2016
Phase: N/A
Study type: Observational [Patient Registry]

The primary aim of the present study is to screen high-risk type 2 diabetes patients and heart failure patients without any history of atrial fibrillation (AF), ongoing oral anticoagulation (OAC) treatment, implanted device or recent stroke/Transient Ischemic Attack (TIA), for silent AF. Moreover, we aim to establish the prevalence of two or more risk factors for stroke in patients with heart failure and diabetes mellitus type 2 (DM2) with the aim of assessing the feasibility for this group to undergo AF screening. Overall, the aim of the study is to prevent stroke in high-risk patients groups through identification of silent (asymptomatic) atrial fibrillation.

NCT ID: NCT02891252 Recruiting - Outpatient Clinical Trials

Randomized Investigation of Thyroid Operation as Day Surgery

Start date: May 2016
Phase: N/A
Study type: Interventional

hemithyroidectomy as a outpatient procedure is performed in some countries, it has never been done a RCT whether it is feasible

NCT ID: NCT02886026 Recruiting - Bladder Cancer Clinical Trials

Outpatient PDD Guided Laser Mediated Destruction of Bladder Tumors

LaserIII
Start date: June 2016
Phase: N/A
Study type: Interventional

This study compare the efficacy of conventional photodynamic (PDD) guided transurethral bladder tumor resection in the operating theatre with outpatient PDD guided laser destruction of bladder tumors through flexible cystoscopes.

NCT ID: NCT02885792 Recruiting - Schizophrenia Clinical Trials

Coronary Artery Disease in Patients Suffering From Schizophrenia

Start date: September 2015
Phase: N/A
Study type: Interventional

Schizophrenia is a severe mental illness associated with excess mortality and affecting nearly 1% of the population. The average life expectancy for patients diagnosed with schizophrenia has been 55-60 years through the last generations in Denmark, while the general population has over the same period of time experienced an increase in life expectancy. As a result, the standardized mortality rate for patients with schizophrenia has increased markedly over the last three decades and is currently a major public health concern. Causes of death are mainly cardiovascular disease and patients diagnosed with schizophrenia has a relative risk of cardiovascular disease that is about 2-fold higher than the general population.